> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Reblozyl Approved for Myelodysplastic Syndromes
- URL: https://www.fdaweb.com/reblozyl-approved-for-myelodysplastic-syndromes/
- Published: 2020-04-06T12:00:00.000Z
- Updated: 2026-09-14T16:10:09.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5146504

FDA has approved a Bristol Myers Squibb and Acceleron Pharma BLA for Reblozyl (luspatercept-aamt), an erythroid maturation agent for treating anemia after failing an erythropoiesis stimulating agent and requiring two or more red blood cell units over eight weeks in adult patients with very low- to intermediate-risk myelodysplastic syndromes with ring sideroblasts or with myelodysplastic/myeloproliferative neoplasm with ring sideroblasts and thrombocytosis. Approval was based on data from the pivotal Phase 3 MEDALIST trial. The therapy was approved 11/2019 for treating anemia in adults with beta thalassemia who require regular transfusions.